Table of Contents
Phase I and II Studies
Patient Exposure
RAPAMUNE Phase I Trials
RAPAMUNE Phase II Trials Renal Transplant Recipients
Phase II Multicenter Trial: RAPAMUNE with Full- vs Reduced-Dose Sandimmune®*
Incidence of Biopsy-Confirmed Acute Rejection (6 Months)
RAPAMUNE Combined With Standard- or Reduced-Dose Cyclosporine: Differences By Race
Phase II Safety Profile of RAPAMUNE Supported Phase III Combination Studies
Rationale for Phase III Trials Dose Selection
|
Author: James Sergi
|